GLP5 (GLP3 R + Cagrilintide)
$111.99
GLP5 is a research peptide blend featuring GLP-3R and Cagrilintide, developed for laboratory investigation into incretin and amylin receptor signaling pathways associated with metabolic and body-weight regulation research.
This peptide is for research purposes only. Not for human consumption.
In stock
Description
Areas in Research
GLP-3R-related peptide research has explored incretin receptor activity and downstream metabolic signaling pathways involved in glucose regulation and energy balance [1]. Cagrilintide is a long-acting amylin analogue studied for its interaction with amylin and calcitonin-family receptors in experimental metabolic models [2],[3]. Research has examined its potential role in appetite signaling, gastric emptying pathways, and body-weight regulation mechanisms [4]. Additional studies have evaluated cagrilintide in combination-based metabolic research models focused on complementary receptor pathway activity [5][6].
For research use only. Not for human consumption.
Referenced Citations
- GLP receptor pathway research: https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
- Cagrilintide PubChem compound data: https://pubchem.ncbi.nlm.nih.gov/compound/Cagrilintide
- Development of cagrilintide: https://pubmed.ncbi.nlm.nih.gov/34288673/
- Cagrilintide and brain amylin receptors: https://pmc.ncbi.nlm.nih.gov/articles/PMC12270663/
- Once-weekly cagrilintide trial: https://pubmed.ncbi.nlm.nih.gov/34798060/
- Combination metabolic research involving cagrilintide: https://pubmed.ncbi.nlm.nih.gov/33894838/
Areas in Research
GLP-3R-related peptide research has explored incretin receptor activity and downstream metabolic signaling pathways involved in glucose regulation and energy balance [1]. Cagrilintide is a long-acting amylin analogue studied for its interaction with amylin and calcitonin-family receptors in experimental metabolic models [2],[3]. Research has examined its potential role in appetite signaling, gastric emptying pathways, and body-weight regulation mechanisms [4]. Additional studies have evaluated cagrilintide in combination-based metabolic research models focused on complementary receptor pathway activity [5][6].
For research use only. Not for human consumption.
Referenced Citations
- GLP receptor pathway research: https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
- Cagrilintide PubChem compound data: https://pubchem.ncbi.nlm.nih.gov/compound/Cagrilintide
- Development of cagrilintide: https://pubmed.ncbi.nlm.nih.gov/34288673/
- Cagrilintide and brain amylin receptors: https://pmc.ncbi.nlm.nih.gov/articles/PMC12270663/
- Once-weekly cagrilintide trial: https://pubmed.ncbi.nlm.nih.gov/34798060/
- Combination metabolic research involving cagrilintide: https://pubmed.ncbi.nlm.nih.gov/33894838/
